



# ***Biosimilars in Hematologic Malignancies & Supportive Care***

## ***Independent Medical Education Competitive Grant Program***

### **I. Background**

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

## II. Eligibility

<b>Geographic Scope:</b>	Global
<b>Applicant Eligibility Criteria</b>	<ul style="list-style-type: none"> <li>• The following may apply medical practitioners, healthcare institutions (both academic and community practices); professional associations and medical societies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.</li> <li>• If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project.</li> <li>• For projects offering continuing education credit, the requesting organization must be accredited.</li> </ul>

## III. Requirements

<b>Date RFP Issued</b>	September 16, 2020
<b>Clinical Area</b>	Oncology - Biosimilars in Hematologic Malignancies & Supportive Care
<b>General Area of Interest for this RFP:</b>	<p>The professional education goal of this RFP is to support the prudent (safe and effective) use of biologic drugs in patients with hematologic malignancies or for use in supportive care by:</p> <ul style="list-style-type: none"> <li>• Increasing clinicians' understanding of complex biosimilar concepts including, the analytical foundation, clinical data analysis for biosimilars and global differences in the regulatory framework governing the approval of biosimilar drugs.</li> <li>• Implementing practical approaches to the incorporation of biosimilars into hematology-oncology practice in all label indications, including protocols, guidelines and pathways. Including, improving the ability of healthcare professionals to discuss biosimilar options with their patients as part of shared-decision-making</li> <li>• Discussing emerging RWE from biosimilars in hematologic malignancies and RWE data gaps preventing full utilization the health care utilization</li> <li>• Discussing available data regarding Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia</li> <li>• Discuss the use of Granulocyte Colony-Stimulating Factors in the</li> </ul>

	<p>SARS-2 (covid19) era and the role of biosimilars to reduce hospital cost burden</p> <ul style="list-style-type: none"> <li>Overcoming global roadblocks to help realize the potential for cost-savings of biosimilars in hematologic malignancies and in supportive care and the overall benefit to reducing healthcare costs in society.</li> </ul> <p>All CME/CE activity types will be considered through this RFP including but not limited to:</p> <ul style="list-style-type: none"> <li>Live or virtual national or regional symposia, workshops, regional community series; online courses &amp; digital tools, handouts &amp; other printed materials</li> <li>Activities for healthcare professionals that also include educational materials or resources for patients</li> <li>Applications from Professional Societies focused on providing education and/or tools to their members are of particular interest.</li> </ul>
<p><b>Target Audience:</b></p>	<ul style="list-style-type: none"> <li>Oncologists/Hematologists, Oncology Nurses, Oncology Pharmacists, Nurse Practitioners, Physician Assistants, Medical residents and fellows</li> </ul>
<p><b>Expected Approximate Monetary Range of Grant Applications:</b></p>	<ul style="list-style-type: none"> <li>Individual projects requesting up to \$200,000 will be considered. The estimated total available budget related to this RFP is \$600,000.</li> <li>Smaller educational proposals are encouraged. Organizations that would like to develop activities for a more limited regional or local group of healthcare providers should also apply. Typically grant amounts for local or regional activities should not exceed around \$50,000 USD.</li> </ul>
<p><b>Key Dates:</b></p>	<ul style="list-style-type: none"> <li>RFP release date: September 15, 2020</li> <li>Grant Application due date: November 2, 2020</li> </ul> <p>Please note the deadline is midnight Eastern Standard Time (e.g. New York, GMT -5).</p> <ul style="list-style-type: none"> <li>Anticipated Grant Award Notification Date: November 19, 2020</li> </ul> <p><i>*Processing time may take longer for organizations outside of the U.S.</i></p> <ul style="list-style-type: none"> <li>Grants will be distributed following a fully executed agreement.</li> <li>Anticipated Project Start and End Dates: January 2021 to June 2022 (dates are suggested, project timelines can be up to 2 years)</li> </ul>

<p><b>How to Submit:</b></p>	<ul style="list-style-type: none"> <li>• Please go to <a href="http://www.cybergrants.com/pfizer/knowledge">www.cybergrants.com/pfizer/knowledge</a> and sign in. First-time users should click “Create your password”.</li> <li>• In the application:             <ul style="list-style-type: none"> <li>○ For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)</li> <li>○ For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select Yes</li> <li>○ Select the following Competitive Grant Program Name: <b>2020 Oncology G: Biosimilars in Hematologic Malignancies &amp; Supportive Care</b></li> <li>○ Select the following Primary Area of Interest: Oncology – General – Biosimilars</li> </ul> </li> </ul> <p>Requirements for submission:</p> <p>Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.</p> <ul style="list-style-type: none"> <li>• If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.</li> </ul> <p><b>IMPORTANT:</b> Be advised applications submitted after the due date will not be reviewed by the committee.</p>
<p><b>Questions:</b></p>	<ul style="list-style-type: none"> <li>• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jackie Waldrop (<a href="mailto:Jacqueline.Waldrop@pfizer.com">Jacqueline.Waldrop@pfizer.com</a>), with the subject line “Biosimilars in Hematologic Malignancies &amp; Supportive Care”</li> </ul>
<p><b>Mechanism by which Applicants will be Notified:</b></p>	<ul style="list-style-type: none"> <li>• All applicants will be notified via email by the dates noted above.</li> <li>• Applicants may be asked for additional clarification during the review period.</li> </ul>

## Appendix A

### General RFP Submission Requirements

**Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:**

<b>Goals and Objectives</b>	<ul style="list-style-type: none"> <li>Briefly state the overall goal of the project.</li> <li>List the objectives you plan to meet with your project, in terms of learning and expected outcomes.</li> </ul>
<b>Needs Assessment for the Project</b>	<ul style="list-style-type: none"> <li>Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.</li> </ul>
<b>Target Audience</b>	<ul style="list-style-type: none"> <li>Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.</li> </ul>
<b>Project Design and Methods</b>	<ul style="list-style-type: none"> <li>Describe the planned project, the educational approach, and the way the planned methods address the established need.</li> </ul>
<b>Innovation</b>	<ul style="list-style-type: none"> <li>Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.</li> </ul>
<b>Evaluation and Outcomes</b>	<ul style="list-style-type: none"> <li>In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.</li> </ul>
<b>Dissemination Plan</b>	<ul style="list-style-type: none"> <li>Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the</li> </ul>

	<p>initial project. Describe how the project outcomes might be broadly disseminated.</p>
<p><b>Anticipated Project Timeline</b></p>	<ul style="list-style-type: none"> <li>• Provide an anticipated timeline for your project including project start/end dates.</li> </ul>
<p><b>Additional Information</b></p>	<ul style="list-style-type: none"> <li>• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.</li> </ul>
<p><b>Organization Detail</b></p>	<ul style="list-style-type: none"> <li>• Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.</li> </ul>
<p><b>Budget Narrative</b></p>	<ul style="list-style-type: none"> <li>• Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application</li> <li>• While estimating your budget please keep the following items in mind:             <ul style="list-style-type: none"> <li>○ Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).</li> <li>○ Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.</li> </ul> </li> </ul>